Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Nanfang Hospital, Southern Medical University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06177925CT.gov A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Respiratory System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Etoposide (this asset) | Nanfang Hospital, Southern Medical University | P2 | CCC · 53 |
| Carboplatin | Nanfang Hospital, Southern Medical University | P3 | BB |
| .Gamma.-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-Octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-Octathio- | Ziekenhuis Oost-Limburg | P4 | BB |
| Rocuronium Ion | Ziekenhuis Oost-Limburg | P4 | BB |
| Neostigmine | Coastal Anesthesiology Consultants | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Nanfang Hospital, Southern Medical University | P3 | BB |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | BB |
| Roflumilast | Prince of Songkla University | P3 | BB |
| Acetylcysteine | Zambon SpA | P3 | B |
+23 more in the Respiratory System Disorder cohort
Other indications for Etoposide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Megakaryoblastic Leukemia | — | P3 | BBB · 79 |
| Acute Monocytic Leukemia | — | P3 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CarboplatinNanfang Hospital, Southern Medical UniversityBB
- .Gamma.-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-Octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-Octathio-Ziekenhuis Oost-LimburgBB
- Rocuronium IonZiekenhuis Oost-LimburgBB
- NeostigmineCoastal Anesthesiology ConsultantsBB
- Cis-Diamminedichloroplatinum IiNanfang Hospital, Southern Medical UniversityBB
Citation
Floatz Terminal. Etoposide in Respiratory System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/etoposide-respiratory-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →